Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Decreases By 60.3%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a large decrease in short interest in the month of June. As of June 30th, there was short interest totaling 597 shares, a decrease of 60.3% from the June 15th total of 1,503 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 3,169 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, Santen Pharmaceutical presently has a consensus rating of “Hold”.

Santen Pharmaceutical Stock Performance

Shares of SNPHY opened at $13.45 on Monday. The company has a market cap of $4.33 billion and a PE ratio of 0.10. The stock has a 50-day moving average price of $12.11 and a 200-day moving average price of $11.37. Santen Pharmaceutical has a 12-month low of $9.22 and a 12-month high of $13.93.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.